Neoadjuvant endocrine therapy 'a reasonable option' for ER-positive breast cancer
Endocrine therapy should be reconsidered as a potential option in the neoadjuvant setting for localised oestrogen receptor-positive breast cancer, say the authors of a meta-analysis.
Threaded Mode